Evidence map›Paper›PMID 41062284›Full record

ArticleThe Journal of veterinary medical science2025

Effect of pimobendan on myocardial injury and systolic dysfunction in a canine model of supraventricular tachyarrhythmia.

Daiki Hirao, Shohei Morita, Hiroshi Hasegewa, Aritada Yoshimura, Takae Kawaguchi, Shusaku Yamada, Takahiro Oomori, Kazuhiko Suzuki, Ryuji Fukushima

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daiki HiraoKoganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Shohei MoritaKoganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Hiroshi HasegewaKoganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Aritada YoshimuraAnimal Medical Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Takae KawaguchiKoganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Shusaku YamadaKoganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Takahiro OomoriKoganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Kazuhiko SuzukiLaboratory of Veterinary Toxicology, Cooperative Department of Veterinary Medicine, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Ryuji FukushimaKoganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Supraventricular tachyarrhythmia (SVTA) in dogs can cause cardiac dysfunction and may progress to heart failure. Pimobendan, an inotropic agent with calcium-sensitizing and phosphodiesterase III inhibition, is widely used in veterinary medicine. However, its influence on myocardial injury under persistent SVTA remains incompletely understood. This study aimed to evaluate whether pimobendan improves systolic function without exacerbating myocardial injury, using a canine model of rapid atrial pacing (RAP). Fourteen healthy Beagle dogs were allocated to either a control or pimobendan group. RAP was performed for three weeks at 390 bpm. Cardiac function was assessed by echocardiography before (baseline) and after RAP (3W). Concurrently, cardiac troponin I (cTnI) concentrations were measured to assess myocardial injury. In the control group, a significant increase in cTnI was observed at 3W compared with baseline (0.023 ± 0.029 ng/mL vs. 0.176 ± 0.173 ng/mL). Additionally, in the control group, echocardiographic parameters worsened, including fractional shortening (FS) (37.8 ± 4.6% vs. 24.5 ± 6.8%) and stroke volume (SV) (15.8 ± 3.1 mL vs. 10.5 ± 2.0 mL) at 3W compared with baseline. In contrast, the pimobendan group showed no significant differences in these echocardiographic parameters. cTnI concentrations also remained within the normal range without significant differences. These results suggest that pimobendan preserved systolic function without aggravating myocardial injury during sustained SVTA. Pimobendan may therefore be safe and effective cardiac inotropic agent for the treatment of dogs with SVTA.

Indexed as

Cardiotonic AgentsDog DiseasesPyridazinesTachycardia, SupraventricularAnimalsDisease Models, AnimalDogsEchocardiographyFemaleMaleSystoleTroponin ICardiotonic AgentspimobendanPyridazinesTroponin Icardiac troponin Idogmyocardial protectionpimobendansupraventricular arrhythmia

Identifiers

PMID41062284
PMCPMC12712197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.